John Hopkins Medicine Collaboration


Study to Test Photobiomodulation Therapy in Parkinson’s Disease Preclinical Mouse Model

BALTIMORE, MD – December 2, 2022: Today, Incando Therapeutics announced the launch of a collaboration with the Johns Hopkins University. Incando, a biotechnology company bringing photomedicine treatments to market with the goal of improving outcomes for patients with cancer and neurodegenerative disease will collaborate with researchers at Johns Hopkins School of Medicine on a study that will test Photobiomodulation Therapy (PBMT) in a mouse model of Parkinson’s disease (PD). PBMT is a light-driven metabolic enhancement that today has some evidence of beneficially affecting brain disorders.

Existing research in this space has shown that α-synuclein (αS) accumulation is the typical pathology hallmark of Parkinson’s disease and other neurodegenerative disorders, and emerging evidence shows that propagation of αS pathology can be a major driver in the development of Parkinson’s disease. The study will address whether PBMT can show benefit in two areas: 1) slowing αS accumulation and 2) slowing neurodegeneration, motor dysfunction, and cognitive impairment among mice included in the study.

“We believe deeply in the potential of photomedicine as treatment for a range of human diseases, and this study is one key step in our journey,” shared Percy Luu, Ph.D., Founder and CEO of Incando Therapeutics. “Our international team of scientists are dedicated to developing novel treatments from cutting edge science that positively impact patients’ lives. We are excited about what our Incando team will be able to explore via this collaboration with Johns Hopkins Medicine.”

The progress currently being sought out could have a major impact for millions of patients around the world because of the potential applications of the photomedicine technology Incando is developing.

“If the study demonstrates efficacy, the wireless implantable NeuroSentry(TM) photomedicine system developed by the Incando Therapeutics team could be on their way to providing much needed treatment options for patients managing αS-related diseases like Parkinson’s, Lewy Body Dementia, and Alzheimer’s disease,” stated Charles Hu, Ph.D., Chief Medical Affairs Officer, Incando Therapeutics.

Once launched, the study will have key markers for pathological evaluation in month 1 and behavioral assessments during months 6-9. Overall, it will take a year for concrete data from neurodegenerative assessments to be delivered. This study will support the company’s near-term plans for human clinical trials against PD.

Incando Therapeutics is an international biotechnology company developing next generation phototherapy solutions for grave diseases. With the mission of advancing photomedicine, Incando Therapeutics is currently developing treatments to improve quality of life and overall outcomes for patients navigating cancer and neurodegenerative disorders. For more information, visit

Download PDF

Create a website or blog at